keyword
MENU ▼
Read by QxMD icon Read
search

Pancreatic neuroendocrine tumour

keyword
https://www.readbyqxmd.com/read/28203372/diagnostic-challenges-and-management-of-a-patient-with-acromegaly-due-to-ectopic-growth-hormone-releasing-hormone-secretion-from-a-bronchial-carcinoid-tumour
#1
Nikolaos Kyriakakis, Jacqueline Trouillas, Mary N Dang, Julie Lynch, Paul Belchetz, Márta Korbonits, Robert D Murray
: A male patient presented at the age of 30 with classic clinical features of acromegaly and was found to have elevated growth hormone levels, not suppressing during an oral glucose tolerance test. His acromegaly was originally considered to be of pituitary origin, based on a CT scan, which was interpreted as showing a pituitary macroadenoma. Despite two trans-sphenoidal surgeries, cranial radiotherapy and periods of treatment with bromocriptine and octreotide, his acromegaly remained active clinically and biochemically...
2017: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/28199314/whole-genome-landscape-of-pancreatic-neuroendocrine-tumours
#2
Aldo Scarpa, David K Chang, Katia Nones, Vincenzo Corbo, Ann-Marie Patch, Peter Bailey, Rita T Lawlor, Amber L Johns, David K Miller, Andrea Mafficini, Borislav Rusev, Maria Scardoni, Davide Antonello, Stefano Barbi, Katarzyna O Sikora, Sara Cingarlini, Caterina Vicentini, Skye McKay, Michael C J Quinn, Timothy J C Bruxner, Angelika N Christ, Ivon Harliwong, Senel Idrisoglu, Suzanne McLean, Craig Nourse, Ehsan Nourbakhsh, Peter J Wilson, Matthew J Anderson, J Lynn Fink, Felicity Newell, Nick Waddell, Oliver Holmes, Stephen H Kazakoff, Conrad Leonard, Scott Wood, Qinying Xu, Shivashankar Hiriyur Nagaraj, Eliana Amato, Irene Dalai, Samantha Bersani, Ivana Cataldo, Angelo P Dei Tos, Paola Capelli, Maria Vittoria Davì, Luca Landoni, Anna Malpaga, Marco Miotto, Vicki L J Whitehall, Barbara A Leggett, Janelle L Harris, Jonathan Harris, Marc D Jones, Jeremy Humphris, Lorraine A Chantrill, Venessa Chin, Adnan M Nagrial, Marina Pajic, Christopher J Scarlett, Andreia Pinho, Ilse Rooman, Christopher Toon, Jianmin Wu, Mark Pinese, Mark Cowley, Andrew Barbour, Amanda Mawson, Emily S Humphrey, Emily K Colvin, Angela Chou, Jessica A Lovell, Nigel B Jamieson, Fraser Duthie, Marie-Claude Gingras, William E Fisher, Rebecca A Dagg, Loretta M S Lau, Michael Lee, Hilda A Pickett, Roger R Reddel, Jaswinder S Samra, James G Kench, Neil D Merrett, Krishna Epari, Nam Q Nguyen, Nikolajs Zeps, Massimo Falconi, Michele Simbolo, Giovanni Butturini, George Van Buren, Stefano Partelli, Matteo Fassan, Kum Kum Khanna, Anthony J Gill, David A Wheeler, Richard A Gibbs, Elizabeth A Musgrove, Claudio Bassi, Giampaolo Tortora, Paolo Pederzoli, John V Pearson, Nicola Waddell, Andrew V Biankin, Sean M Grimmond
The diagnosis of pancreatic neuroendocrine tumours (PanNETs) is increasing owing to more sensitive detection methods, and this increase is creating challenges for clinical management. We performed whole-genome sequencing of 102 primary PanNETs and defined the genomic events that characterize their pathogenesis. Here we describe the mutational signatures they harbour, including a deficiency in G:C > T:A base excision repair due to inactivation of MUTYH, which encodes a DNA glycosylase. Clinically sporadic PanNETs contain a larger-than-expected proportion of germline mutations, including previously unreported mutations in the DNA repair genes MUTYH, CHEK2 and BRCA2...
February 15, 2017: Nature
https://www.readbyqxmd.com/read/28197876/enhancing-pancreatic-mass-with-normal-serum-ca19-9-key-mdct-features-to-characterize-pancreatic-neuroendocrine-tumours-from-its-mimics
#3
Liang Zhu, Hua-Dan Xue, Wei Liu, Xuan Wang, Xin Sui, Qin Wang, Daming Zhang, Ping Li, Zheng-Yu Jin
OBJECTIVES: To determine key MDCT features for characterizing pancreatic neuroendocrine tumours (PNET) from their mimics, which manifest as enhancing pancreatic mass with normal serum CA19-9 level. METHODS: This retrospective study had institutional review board approval and informed consent was waived. Preoperative multiphase MDCT of 74 patients with enhancing pancreatic masses and normal serum CA19-9 levels were included. Surgical pathologies were PNET (n = 42), microcystic serous cystadenomas (m-SCN, n = 12) and solid pseudopapillary epithelial neoplasms (SPEN, n = 20)...
February 15, 2017: La Radiologia Medica
https://www.readbyqxmd.com/read/28179320/detection-of-somatic-mutations-in-gastroenteropancreatic-neuroendocrine-tumors-using-targeted-deep-sequencing
#4
Samuel Backman, Olov Norlén, Barbro Eriksson, Britt Skogseid, Peter Stålberg, Joakim Crona
: Mutations affecting the mechanistic target of rapamycin (MTOR) signalling pathway are frequent in human cancer and have been identified in up to 15% of pancreatic neuroendocrine tumours (NETs). Grade A evidence supports the efficacy of MTOR inhibition with everolimus in pancreatic NETs. Although a significant proportion of patients experience disease stabilization, only a minority will show objective tumour responses. It has been proposed that genomic mutations resulting in activation of MTOR signalling could be used to predict sensitivity to everolimus...
2017: Anticancer Research
https://www.readbyqxmd.com/read/28155290/the-diagnosis-of-bilateral-primary-renal-paragangliomas-in-a-cat
#5
Ryan B Friedlein, Alain J Carter, Robert D Last, Sarah Clift
A 9-year-old sterilised female domestic short-hair cat was referred with a history of vomiting and anorexia of 3 months' duration. Biochemistry, full-blood counts, thoracic radiographs, feline pancreatic-specific lipase, abdominal ultrasonography and feline immunodeficiency virus/feline leukaemia virus (FIV/FeLV) SNAP tests had been performed. Mild hypochloraemia and moderate hypokalaemia were evident on initial presentation. Abdominal ultrasonography initially revealed unilateral renal nodules on the left side...
January 24, 2017: Journal of the South African Veterinary Association
https://www.readbyqxmd.com/read/28152531/chemotherapy-in-well-differentiated-pancreatic-neuroendocrine-tumours-with-ki-67-%C3%A2-10-is-there-a-more-effective-antitumor-regimen-a-retrospective-multicentric-study-of-the-french-group-of-endocrine-tumours-gte
#6
Guillaume Roquin, Eric Baudin, Catherine Lombard-Bohas, Guillaume Cadiot, Sophie Dominguez, Rosine Guimbaud, Patricia Niccoli, Jean-Louis Legoux, Emmanuel Mitry, Vincent Rohmer, Philippe Ruszniewski, Thomas Walter, Michel Ducreux, Anne Couvelard, Jean-Yves Scoazec, Aline Ramond-Roquin, François-Xavier Caroli-Bosc, Olivia Hentic
No abstract text is available yet for this article.
February 3, 2017: Neuroendocrinology
https://www.readbyqxmd.com/read/28122378/sequential-everolimus-and-sunitinib-treatment-in-pancreatic-metastatic-well-differentiated-neuroendocrine-tumours-resistant-to-prior-treatments
#7
Anna Angelousi, Kimberly Kamp, Maria Kaltsatou, Dermot O'Toole, Gregory Kaltsas, Wouter de Herder
No abstract text is available yet for this article.
January 26, 2017: Neuroendocrinology
https://www.readbyqxmd.com/read/28111046/validation-and-comparison-between-current-prognostication-systems-for-pancreatic-neuroendocrine-neoplasms-a%C3%A2-single-institution-experience-with-176-patients
#8
Roxanne Teo, Brian K P Goh, David W M Tai, John C Allen, Tony K H Lim, Jacqueline S G Hwang, Damien M Tan, Ser-Yee Lee, Chung-Yip Chan, Peng-Chung Cheow, Pierce K H Chow, London L P J Ooi, Alexander Y F Chung, Simon Ong
BACKGROUND: This article aims to validate and compare the performance of 6 prognostication systems-the World Health Organization 2010 grading criteria, the European Neuroendocrine Tumour Society and the American Joint Committee for Cancer staging systems, the Memorial Sloan Kettering Cancer Center staging and grading systems, as well as the Bilimoria criteria in a cohort of patients with pancreatic neuroendocrine neoplasms at a single institution. METHODS: A retrospective review of 176 patients with histologically proven pancreatic neuroendocrine neoplasm was performed...
January 19, 2017: Surgery
https://www.readbyqxmd.com/read/28062742/emphysematous-cholecystitis-in-a-patient-with-metastatic-pancreatic-neuroendocrine-tumour
#9
M Khan, M Little, G Campbell, H-U Laasch, T Cooksley
No abstract text is available yet for this article.
January 5, 2017: QJM: Monthly Journal of the Association of Physicians
https://www.readbyqxmd.com/read/28027897/relevance-of-dihydropyrimidine-dehydrogenase-and-thymidylate-synthase-in-patients-with-pancreatic-neuroendocrine-neoplasms-treated-with-5-fu-based-chemotherapy
#10
S Krug, M Boch, W Nimphius, T M Gress, P Michl, A Rinke
BACKGROUND: Chemotherapy with 5-FU and Streptozotocin (STZ) is recommended as first-line treatment in patients with metastatic pancreatic neuroendocrine neoplasms (PNEN). However, data about biomarkers involved in the 5-FU metabolism to predict response are still limited. OBJECTIVES: Evaluation of clinicopathological features and potential predictive and prognostic markers of patients with PNEN treated with 5-FU based regimens. PATIENTS AND METHODS: We retrospectively analyzed 41 patients with PNEN who were treated at the University Hospital Marburg between 2000 and 2013...
December 22, 2016: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
https://www.readbyqxmd.com/read/27959889/childhood-neuroendocrine-tumours-a-descriptive-study-revealing-clues-for-genetic-predisposition
#11
I J Diets, I D Nagtegaal, J Loeffen, I de Blaauw, E Waanders, N Hoogerbrugge, M C J Jongmans
BACKGROUND: Neuroendocrine tumours (NETs) are rare in children and limited data are available. We aimed to specify tumour and patient characteristics and to investigate the role of genetic predisposition in the aetiology of paediatric NETs. METHODS: Using the Dutch Pathology Registry PALGA, we collected patient- and tumour data of paediatric NETs in the Netherlands between 1991 and 2013 (N=483). RESULTS: The incidence of paediatric NETs in the Netherlands is 5...
January 17, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/27956320/primary-tumour-resection-may-improve-survival-in-functional-well-differentiated-neuroendocrine-tumours-metastatic-to-the-liver
#12
D Citterio, S Pusceddu, A Facciorusso, J Coppa, M Milione, R Buzzoni, M Bongini, F deBraud, V Mazzaferro
BACKGROUND: Functional well-differentiated neuroendocrine tumours (NET) with liver metastases represent a therapeutic challenge with few alternative options in guidelines. In these patients, the role of surgical resection of the primary tumour is controversial. PATIENTS AND METHODS: From a regional registry collecting somatostatin analogue (SSA)-treated tumours from 1979 to 2005, a series of 139 patients presenting with symptomatic, liver-metastatic, well-differentiated NET (G1-G2, mitoses: ≤20, Ki-67: ≤20%) was prospectively collected and retrospectively analysed...
February 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27890421/contrast-enhanced-mdct-in-patients-with-pancreatic-neuroendocrine-tumours-correlation-with-histological-findings-and-diagnostic-performance-in-differentiation-between-tumour-grades
#13
E Belousova, G Karmazanovsky, A Kriger, D Kalinin, L Mannelli, A Glotov, N Karelskaya, O Paklina, A Kaldarov
AIM: To identify the multidetector computed tomography (MDCT) features of pancreatic neuroendocrine tumours (pNETs), which correlate with tumour histology and enable preoperative grading. MATERIALS AND METHODS: Thirty-nine patients with histologically confirmed pNET who underwent preoperative contrast-enhanced MDCT were included in this study. Nineteen tumours were classified as Grade 1 (G1) and 20 as Grade 2 (G2). Histopathology slides were reviewed to assess the intratumoural microvascular density (MVD) and the amount of tumour stroma...
February 2017: Clinical Radiology
https://www.readbyqxmd.com/read/27875519/expression-of-somatostatin-receptors-2-and-5-in-circulating-tumour-cells-from-patients-with-neuroendocrine-tumours
#14
Alexa Childs, Clare Vesely, Leah Ensell, Helen Lowe, Tu Vinh Luong, Martyn E Caplin, Christos Toumpanakis, Christina Thirlwell, John A Hartley, Tim Meyer
BACKGROUND: Neuroendocrine tumours (NET) overexpress somatostatin receptors (SSTR) that can be targeted for therapy. Somatostatin receptor expression is routinely measured by molecular imaging but the resolution is insufficient to define heterogeneity. We hypothesised that SSTR expression could be measured on circulating tumour cells (CTCs) and used to investigate heterogeneity of expression and track changes during therapy. METHODS: MCF-7 cells were transfected with SSTR2 or 5 and spiked into donor blood for analysis by CellSearch...
December 6, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27863693/surgical-treatment-of-non-functioning-pancreatic-neuroendocrine-tumours-based-on-three-clinical-scenarios
#15
Juli Busquets, Elena Ramírez-Maldonado, Teresa Serrano, Núria Peláez, Luís Secanella, Sandra Ruiz-Osuna, Emilio Ramos, Laura Lladó, Juan Fabregat
INTRODUCTION: The treatment of patients with non-functioning pancreatic neuroendocrine tumours (NFPNET) is resection in locally pancreatic disease, or with resectable liver metastases. There is controversy about unresectable liver disease. METHODS: We analysed the perioperative data and survival outcome of 63 patients who underwent resection of NFPNET between 1993 and 2012. They were divided into 3 scenarios: A, pancreatic resection (44patients); B, pancreatic and liver resection in synchronous resectable liver metastases (12patients); and C, pancreatic resection in synchronous unresectable liver metastases (6patients)...
December 2016: Cirugía Española
https://www.readbyqxmd.com/read/27821081/management-of-controversial-gastroenteropancreatic-neuroendocrine-tumour-clinical-situations-with-somatostatin-analogues-results-of-a-delphi-questionnaire-panel-from-the-netpraxis-program
#16
Isabel Sevilla, Ángel Segura, Jaume Capdevila, Carlos López, Rocío García-Carbonero, Enrique Grande
BACKGROUND: There are clinical situations (CS) in which the use of somatostatin analogs (SSAs) in patients with neuroendocrine tumors (NET) is controversial due to lack of evidence. A Delphi study was conducted to develop common treatment guidelines for these CS, based on clinical practice and expert opinion of Spanish oncologists. METHODS: A scientific committee identified 5 CS with a common core (c-c) [non-functioning NET, not susceptible of surgery/locoregional therapy, Ki67 < 10 % (except for CS5: >10 %), ECOG ≤ 2], and controversy regarding use of SSAs, and prepared a Delphi questionnaire of 48 treatment statements...
November 7, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27811856/predictive-factors-of-antiproliferative-activity-of-octreotide-lar-as-first-line-therapy-for-advanced-neuroendocrine-tumours
#17
Faidon-Marios Laskaratos, Martin Walker, Keval Naik, Emmanouil Maragkoudakis, Nikolaos Oikonomopoulos, Lee Grant, Tim Meyer, Martyn Caplin, Christos Toumpanakis
BACKGROUND: The antiproliferative activity of octreotide LAR in neuroendocrine tumours (NETs) has been demonstrated by small retrospective studies and confirmed by a prospective phase III trial (PROMID). However, there are limited data about the duration and predictors of response. The aim of our retrospective study was to determine the time to radiological progression (TTRP) of disease and the factors that were associated with better response. METHODS: A total of 254 treatment naïve patients with advanced NETs and positive somatostatin receptor scintigraphy were included...
November 22, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27803081/renal-neuroendocrine-tumour-and-synchronous-pancreas-metastasis-histopathological-diagnosis-using-prostatic-acid-phosphatase
#18
Keishi Kawasaki, Yoshikuni Kawaguchi, Yoshio Suzuki, Nobutaka Tanaka
A woman aged 56 years developed 2 synchronous tumours: one, 1.2 cm in diameter at the head of the pancreas; and the other, 4.0 cm in diameter, at the left side of her horseshoe kidney. Preoperative differential diagnosis of these hypovascular lesions included pancreatic ductal carcinoma (PDC) with renal metastasis, PDC with renal angiomyolipoma, renal cell carcinoma with pancreatic metastasis or PDC and renal cell carcinoma. Following pancreaticoduodenectomy and left nephrectomy, both specimens were diagnosed as grade 2 neuroendocrine tumours (NETs)...
November 1, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27742480/assessing-the-role-of-primary-tumour-resection-in-patients-with-synchronous-unresectable-liver-metastases-from-pancreatic-neuroendocrine-tumour-of-the-body-and-tail-a-propensity-score-survival-evaluation
#19
E Bertani, N Fazio, D Radice, C Zardini, G Spinoglio, A Chiappa, D Ribero, R Biffi, S Partelli, M Falconi
BACKGROUND: The role of primary tumour surgery in pancreatic neuroendocrine tumours (PNETs) with unresectable liver metastases is controversial and international guidelines do not recommend surgery in such cases. Resectability of the primary tumour has never been considered in outcome comparisons between operated and non-operated patients. METHODS: From two institutional prospective databases of patients affected by PNET and unresectable liver metastases, 63 patients who underwent a left-pancreatectomy at diagnosis were identified and compared with a group of 30 patients with a potentially resectable but not-resected primary tumour located in the body or tail...
February 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27710813/potential-clinical-indications-for-a-cck2-receptor-antagonist
#20
REVIEW
Malcolm Boyce, Katie A Lloyd, D Mark Pritchard
Gastrin controls gastric acid secretion and mucosal cell growth, especially of enterochromaffin-like cells, via gastrin/cholecystokinin-2 receptor (CCK2R) binding and downstream signalling. Studies in animal models, healthy subjects and patients with gastric neuroendocrine tumours provide compelling evidence to justify developing a CCK2R antagonist (CCK2RA) for preventing or treating the trophic effects of hypergastrinaemia or conditions expressing CCK2R, and with or without a proton pump inhibitor, for treating gastric acid-related conditions...
December 2016: Current Opinion in Pharmacology
keyword
keyword
61812
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"